Seroprevalence survey on measles, mumps, rubella and varicella antibodies in healthcare workers in Japan: Sex, age, occupational-related differences and vaccine efficacy

Epidemiology and Infection

Volumn 142, Issue 1, 2014, Pages 12-19

  Kumakura, S ^a   Shibata, H ^a   Onoda, K ^a   Nishimura, N ^a   Matsuda, C ^a   Hirose, M ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Healthcare workers; Measles; Mumps; Rubella; Seroprevalence survey; Vaccination; Varicella

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; HERPES ZOSTER IMMUNOGLOBULIN; MEASLES ANTIBODY; MUMPS ANTIBODY; RUBELLA ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; AGE DISTRIBUTION; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CHICKENPOX; CONTROLLED STUDY; DRUG SAFETY; ENZYME IMMUNOASSAY; FEMALE; HEALTH CARE PERSONNEL; HUMAN; INFECTION CONTROL; JAPAN; MALE; MEASLES; MIDDLE AGED; MUMPS; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; RUBELLA; SEROCONVERSION; SEROPREVALENCE; SEX DIFFERENCE; UNIVERSITY HOSPITAL; VACCINATION;

EID: 84890074319     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268813000393     Document Type: Article

References (25)

1. Centers for Disease Control and Prevention. Progress toward measles elimination - Japan, 1999-2008. Morbidity and MortalityWeekly Report 2008; 57: 1049-1052
2. Infectious Disease Surveillance Center. (http://www. nih.go.jp/niid/ja/ idwr/2085-ydata/1617-report-jb.html) [in Japanese]. Accessed 21 December 2012
3. Centers for Disease Control and Prevention. Immunization of healthcare workers: Recommendation of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). Morbidity and Mortality Weekly Report. Recommendations and Reports 1997; 46: 1-42
4. Bolyard EA, et al. Guideline for infection control in healthcare personnel, 1998. Hospital Infection Control Practices Advisory Committee. Infection Control and Hospital Epidemiology 1998; 19: 407-463
5. Hatakeyama S, et al. Prevalence of measles, rubella, mumps, and varicella antibodies among healthcare workers in Japan. Infection Control and Hospital Epidemiology 2004; 25: 591-594
6. Asari S, et al. Seroprevalence survey of measles, rubella, varicella, and mumps antibodies in health care workers and evaluation of a vaccination program in a tertiary care hospital in Japan. American Journal of Infection Control 2003; 31: 157-162
7. Vagholkar S, et al. Healthcare workers and immunity to infectious diseases. Australian and New Zealand Journal of Public Health 2008; 32: 367-371
8. Fedeli U, Zanetti C, Saia B. Susceptibility of healthcare workers to measles, mumps rubella and varicella. Journal of Hospital Infection 2002; 51: 133-135
9. Celikbas A, et al. Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: Is prevaccination screening cost-effective? American Journal of Infection Control 2006; 34: 583- 587
10. Almuneef MA, et al. Seroprevalence survey of varicella, measles, rubella, and hepatitis A and B viruses in a multinational healthcare workforce in Saudi Arabia. Infection Control and Hospital Epidemiology 2006; 27: 1178-1183
11. Infectious Disease Surveillance Center. Measles, Japan, 2006-2007. (http://idsc.nih.go.jp/iasr/28/331/tpc331.html). Accessed 15 September 2012
12. Infectious Disease Surveillance Center. Measles in Japan, 2009. (http://idsc.nih.go.jp/iasr/31/360/tpc360. html). Accessed 15 September 2012
13. Sadzot-Delvaux C, et al. Varicella vaccination in Japan, South Korea, and Europe. Journal of Infectious Diseases 2008; 197 (Suppl. 2): 185-190
14. Infectious Disease Surveillance Center. (http://idsc.nih. go.jp/yosoku/Rubella/Serum-R2009-e.html). Accessed 21 December 2012
15. Kaetsu A, et al. An outbreak of measles in Saitama City in 2007. What is the vaccination strategy to eliminate measles in Japan? Journal of Infection and Chemotherapy 2008; 14: 291-295
16. Clifford HD, et al. Polymorphisms in key innate immune genes and their effects on measles vaccine responses and vaccine failure in children from Mozambique. Vaccine 2012; 30: 6180-6185
17. de Melker H, et al. The seroepidemiology of measles in Western Europe. Epidemiology and Infection 2001; 126: 249-259
18. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. New England Journal of Medicine 2007; 357: 1903-1915
19. Lee MS, et al. Protective titres of measles neutralising antibody. Journal of Medical Virology 2000; 62: 511- 517
20. Tharmaphornpilas P, et al. Seroprevalence of antibodies to measles, mumps, and rubella among Thai population: Evaluation of measles/MMR immunization programme. Journal of Health, Population and Nutrition 2009; 27: 80-86
21. Maple PA, et al. Comparison of the performance of the LIAISON VZV-IgG and VIDAS automated enzyme linked fluorescent immunoassays with reference to a VZV-IgG time-resolved fluorescence immunoassay and implications of choice of cut-off for LIAISON assay. Journal of Clinical Virology 2009; 44: 9-14
22. Skendzel LP. Rubella immunity. Defining the level of protective antibody. American Journal of Clinical Pathology 1996; 106: 170-174
23. Matter L, Kogelschatz K, Germann D. Serum levels of rubella virus antibodies indicating immunity: Response to vaccination of subjects with low or undetectable antibody concentrations. Journal of Infectious Diseases 1997; 175: 749-755
24. Backhouse JL, et al. Evaluation of two enzyme immunoassays for detection of immunoglobulin G antibodies to mumps virus. Clinical and Vaccine Immunology 2006; 13: 764-767
25. Davidkin I, et al. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: A 20-year follow-up. Journal of Infectious Diseases 2008; 197: 950-956